Biotech Daily

Wednesday August 5, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: IMPEDIMED UP 25%; MICRO-X DOWN 6.5%**

*** NEUREN H1 DAYBUE ROYALTY UP 16% TO $33m, SALES UP 25% TO $321m**

*** MEMPHASYS $350k POLAND FELIX CONTRACT**

*** CLARITY '74% OF 8GBq CU-67 SAR-BIS-PSMA PATIENTS REDUCED PSA'**

*** BLINKLAB 'Dx2 82% SENSITIVITY, 83% SPECIFICITY FOR ADHD'**

*** ADALTA: '2 MESOTHELIOMA COMPLETE RESPONSES TO EW-001'**

*** QUEENSLAND UNI USES A.I. FOR FOOT HEALTH**

*** SAHMRI TO DEVELOP CHRONIC VISCERAL PAIN THERAPIES**

*** PROTEOMICS EX M-D DR RICHARD LIPSCOMBE REDUCES TO 10%**

*** MARK AZZI TAKES 10% OF NYRADA**

*** MAYNE APPOINTS JACOB MA-WEAVER DIRECTOR**

MARKET REPORT

The Australian stock market was up 0.9 percent on Wednesday August 5, 2026, with the ASX200 up 82.0 points to 9,227.8 points. Twenty-two of the Biotech Daily Top 40 companies were up, eight fell and 10 traded unchanged.

Yesterday's 0.1 cents or 20 percent worst, Impedimed, was today's best, up 0.1 cents or 25 percent to 0.5 cents, with 17.3 million shares traded.

Neuren climbed 16.3 percent; Proteomics was up 14.3 percent; 4D Medical and Artrya were up more than nine percent; Clarity climbed 7.1 percent; Starpharma was up 6.7 percent; Compumedics, Pro Medicus and Racura rose more than four percent; EBR, Medical Developments, Nanosonics, Nova Eye, Saluda and Syntara were up three percent or more; Clinuvel, Imugene, Mesoblast, Prescient, Resmed and Telix rose more than two percent; Aroa and CSL were up more than one percent; with Avita up by 0.8 percent.

Micro-X led the falls, down 0.2 cents or 6.45 percent to 2.9 cents, with 1.96 million shares traded. Both Curvebeam and Paradigm lost 5.3 percent; Emvision was down 3.5 percent; Alcidion and Cyclopharm shed more than two percent; Imricor was down one percent; with Cochlear and Polynovo down by less than one percent.

NEUREN PHARMACEUTICALS

Neuren says Acadia net Daybue sales for the six months to June 30, 2026 rose 24.9 percent to $US226 million ($A321 million), with royalties up 16.0 percent to $A32.7 million.
Neuren said sales of trofenitide for Rett syndrome, marketed by North America partner Acadia Pharmaceuticals as Daybue, for the three months to June 30, 2026 were up 24 percent to $US125 million, “the highest quarterly sales since launch”.
The company said it had three-month royalties of $US12.9 million ($A18.3 million), with the sales record “almost entirely volume-driven, as strong Daybue Stix adoption exceeding expectations”.
In 2023, Neuren said San Diego’s Acadia had US Food and Drug Administration approval for Daybue for Rett syndrome for people over the age of two years (BD: Mar 13, 2023).
Last year, the company said sales for the six months to June 30, 2025 rose 12.6 percent to $US180.7 million, with royalties of $A28.2 million; and earlier this year, said sales for the three months to March 31, 2026 were up 19.4 percent to $US101 million, with $US10.4 million ($A14.4 million) in royalties (BD: Aug 7, 2025; May 7, 2026).
Today, Neuren said its Daybue Stix trofinetide powder formulation had been available in the US since April and about 45 percent of Stix demand “came from new or returning patients”, with 40 percent of all US patients receiving Stix by the end of the three months.
The company said its launch in Germany was expected early in the three months to December 31, 2026, subject to European Commission marketing authorization, and it was eligible to receive $US35 million following the first commercial sale and $US170 million in additional milestones as well as tiered royalties on future sales.
Neuren said it expected Japan trofinetide trial results by November, with a filing in 2027.
The company said Acadia increased full-year guidance from $US460-490 million to $US480-510 million, with royalty income up from $US50-54 million to $US53-56 million.
Neuren managing-director Jon Pilcher said the strong sales growth reflected “the early success of Stix in the US, as well as achievement of the positive [European] opinion, both important steps toward bringing trofinetide to more patients with Rett syndrome globally”.
Neuren was up $3.03 or 16.3 percent to $21.64 with 2.4 million shares traded.

MEMPHASYS

Memphasys says it has a $350,000 contract with Warsaw’s TK Biotech SP for the sale and commercialization of its Felix sperm separation system in Poland.
Last year, Memphasys said it was granted Conformité Européenne (CE) mark to commercialize its Felix automated sperm selection system (BD: Jan 18, 2026).
Today, the company said the contract included a three-month evaluation period followed by a two-year commercial term, with minimum purchases of $350,000 and an initial order to support product training, clinic demonstrations and early market introduction.
Memphasys said following the evaluation period, contracted quarterly purchase commitments would begin immediately and “increase materially in the second agreement year”, with the initial evaluation order expected to be invoiced by October 2026 with the first minimum quarterly purchase order expected by the end of 2026.
The company said Poland’s IVF sector was “expanding following the introduction of the Polish Government’s publicly funded IVF program in June 2024”.
The company said the program was operating in 58 fertility clinics, had qualified more than 51,000 couples and had resulted in 29,806 clinical pregnancies and 15,000 births, which provided “a supportive market environment for reproductive technologies that can improve patient clinical outcomes and clinical workflow efficiency”.
Memphasys was unchanged at 0.7 cents with 4.9 million shares traded.

CLARITY PHARMACEUTICALS

Clarity says 14 of 19 patients (73.7%) dosed with 8.0GBq of copper-67 Sar-Bis-PSMA achieved a prostate specific antigen (PSA) reduction of more than 25 percent.
In 2023, Clarity said it treated the first of 44 patients in its 'Secure' phase I/IIa trial of copper-67 Sar-bis-prostate specific membrane antigen (PSMA) for metastatic non-resectable prostate cancer; and last year said it had treated the first of 24 patients in the expansion cohort of its phase II trial of 8.0GBq (giga-becquerels) of copper-67 Sar-Bis-PSMA for prostate cancer (BD: May 24, 2023; Apr 15, 2025).
Today, Clarity said the preliminary assessment included all participants who received 8GBq treatment cycles, or 16 patients from the ongoing cohort expansion phase and three participants from cohort two of the dose escalation phase at data cut-off on July 20, 2026.
The company said 12 patients (63.2%) achieved a more than or equal to 50 percent reduction in PSA, with 10 patients (52.6%) at a more than or equal to 75 percent reduction and five patients (26.3%) reporting a more than 90 percent reduction.
Clarity said responses continued "to mature in participants remaining on treatment" and the cohort expansion was treating existing patients and additional patients.
The company said 13 of 16 patients (81.25%) eligible for radiographic assessment at the data cut-off, achieved disease control, with eight patients reporting stable disease and a complete response or undetectable disease in five patients.
Clarity said two evaluable patients at data cut-off in the cohort expansion phase of the trial achieved a complete response, bringing the total number of patients with complete responses to seven, five of which were from the 8GBq dose cohorts.
The company said the most common related adverse events were gastro-intestinal and haematological disorders, with the majority mild-or-moderate and transient.
Clarity was up 18 cents or 7.1 percent to $2.70 with six million shares traded.

BLINKLAB

Blinklab says a European study of 208-children shows its Dx2 algorithm had 82 percent sensitivity and 83 percent specificity for attention deficit hyperactivity disorder (ADHD).
Earlier this year, Blinklab said it had recruited about 375 patients in its European study with Mental Care Group of its Dx2 smartphone test for ADHD (BD: Jun 26, 2026).
Today, the company said of the 375 children recruited those with co- neuro-developmental or psychiatric conditions, and those on medication were excluded to establish a defined ADHD group and a clean comparison group; with the 208 children including 117 diagnosed with ADHD and 91 with no diagnosis of any neuro-developmental condition.
The company said its "smartphone-derived objective neuro-metric markers were positively associated with subjective clinical observations documented in participants' … reports".
Blinklab said the results were "the first evidence that digital neuro-behavioral bio-markers can detect differences associated with ADHD [and] … the observed correlation between these biomarkers and clinical observations recorded in ADHD diagnostic reports provides further support that the measures reflect clinically relevant features".
The company said the findings were not designed to support regulatory submissions; and further clinical validation, model improvement and regulatory clearance were required before the technology could be used as an ADHD diagnostic aid.
Blinklab said it would use the findings to advance the development of Dx2 and planned to begin a US pilot study followed by a prospective registrational study.
Blinklab managing-director Dr Henk-Jan Boele said there was no blood test or brain scan for ADHD and diagnosis was a subjective clinical judgement.
Blinklab was up six cents or 8.9 percent to 73.5 cents.

ADALTA

Adalta says two of 10 patients (20%) reported a complete response in a China study of EW-001, formerly BZDS1901, for advanced mesothelioma.

In January, Adalta said its Adcella 'East-to-West' strategy would invest up-to $US31 million to develop Shanghai Cell Therapy Group's BZDS1901 for mesothelioma outside China and in July said it paid a $US1 million milestone to Shanghai Cell for five additional mesothelioma patients treated with BZDS1901 in China (BD: Jan 18, 21; Jul 1, 2026).

Today, Adalta said one patient with a complete response, or complete tumor clearance, after a single dose of EW-001, had passed two years survival without recurrence, with the second complete responder reaching the one-year survival milestone.

The company said the study showed a "level of complete tumor clearance that is almost never seen in advanced mesothelioma where published second line [complete responses] are typically zero percent".

Adalta said it was advancing the transfer of EW-001 manufacturing to Cell Therapies in Australia and preparing for a pre-investigational new drug meeting with the US Food and Drug Administration, both expected by 2027.

Adalta managing-director Dr Tim Oldham said complete tumor clearance was "almost never seen in patients with advanced mesothelioma".

"To have achieved it in two of the 10 patients treated at the higher EW-001 doses is highly encouraging, and to see the first of those patients still free of cancer recurrence two years after a single infusion is the kind of result that changes the conversation with patients, regulators and partners," Dr Oldham said.

Adalta was up 0.05 cents or 14.3 percent to 0.4 cents with 20.6 million shares traded.

THE UNIVERSITY OF QUEENSLAND

The University of Queensland says a 35-patient study shows artificial intelligence (A.I.) could be used to develop simpler, lower-cost technologies for monitoring foot health.

The University of Queensland said with Brisbane's Iorthotics and Healthia it "produced an A.I. model capable of reconstructing detailed foot pressure maps using information about foot shape and a small number of anatomical pressure points".

The University said the A.I. system "could help unlock practical and more accessible methods to reconstruct dense plantar pressure information from sparse sensing".

The University of Queensland said the study used anatomical foot information and plantar pressure measurements from 35 participants and developed "an artificial neural network framework capable of generating accurate, high-resolution pressure maps using significantly fewer physical sensors".

The University said the study, titled 'Multimodal Feature-Level Fusion CBAM U-Net for Static Plantar Pressure Prediction Using Plantar Geometry and Sparse Anatomical Landmarks' was published in Sensors and available at: https://bit.ly/4fTGAsw.

The University of Queensland said the model "achieved its best performance using just 16 anatomical 'landmarks' from the bottom of the foot and achieved a comparable result using only two landmarks, indicating promising reconstruction performance even under very limited sensing conditions".

The University's Prof Martin Veidt said existing measurement methods had "limitations and are often costly and inaccessible for people living in rural and remote regions".

"This research demonstrates that by combining information about foot shape with only a small number of anatomical inputs, it is possible to reconstruct detailed plantar pressure distributions with a high degree of accuracy," Prof Veidt said. "The beauty is that data collection could feasibly take place anywhere, including in isolated communities."

SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE

SAHMRI says it will develop therapies for chronic visceral pain associated with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and endometriosis.
SAHMRI said the five-year program was funded by a Federal Government National Health and Medical Research Council (NHMRC) Investigator Grant awarded to Prof Stuart Brierley, director of its Visceral Pain Research Group.
The Institute said the program would "investigate how hypersensitive nerve pathways drive pain originating from internal organs and test innovative therapies designed to interrupt those signals before they reach the brain and spinal cord".
SAHMRI said the program would use "validated models of IBS, IBD and endometriosis alongside patient-derived laboratory models to better understand the biological mechanisms responsible for persistent pain and identify new therapeutic targets" and researchers would investigate a range of approaches, including venom-derived peptides and engineered proteins designed to target pain-signalling pathways.

PROTEOMICS INTERNATIONAL LABORATORIES

Former Proteomics managing-director Dr Richard Lipscombe says he has reduced his substantial holding from 17,146,855 shares (10.37%) to 16,317,855 shares (9.87%).
The Perth-based Dr Lipscombe said that he sold 829,000 shares between July 8 and 23, 2026 for $147,554, or 17.8 cents a share.
Last year, Proteomics said founder Dr Lipscombe would retire in February 2026, coinciding with his 25th anniversary with the company (BD: Sep 9, 2025).
Proteomics was up two cents or 14.3 percent to 16 cents.

NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding in the company from 22,933,865 Chess depository interests (CDIs) (9.28%) to 25,568,254 CDIs (10.35%).
Nyrada did not disclose the cost of the additional shares in Mr Azzi's holding.
Nyrada fell half a cent or 0.7 percent to 74 cents.

MAYNE PHARMA

Mayne Pharma says it has appointed Jacob Ma-Weaver as a non-executive director, effective from August 14, 2026.
Mayne said the San Francisco-based Mr Ma-Weaver was the founding managing member of investment adviser Cable Car Capital, the general partner of hedge fund Funicular Funds, which held 9.90 percent of the company.
The company said Mr Ma-Weaver had been a director of ARCA Biopharma and an investment analyst at Amici Capital, research associate at Dodge & Cox and business analyst at McKinsey & Co.
Mayne said Mr Ma-Weaver held a Bachelor of Arts and a Master of Arts from Columbia University.
Mayne was up eight cents or 2.6 percent to $3.13 with 407,668 shares traded.